In an adult patient with a Providencia stuartii infection resistant to quinolones and aminoglycosides but susceptible to ertapenem, and meropenem unavailable, should ertapenem be used?

Should Ertapenem Be Used for Providencia stuartii When Meropenem is Unavailable?

Yes, ertapenem should be used if the isolate is susceptible to ertapenem on in vitro testing, particularly for non-severe infections or when newer agents are unavailable. However, recognize that ertapenem has important limitations compared to meropenem for this pathogen.

Key Decision Points

When Ertapenem is Appropriate:

• Documented ertapenem susceptibility on culture is essential—do not use empirically 1
• Non-severe infections (uncomplicated UTI, mild intra-abdominal infections) where the organism is susceptible 2
• Source control achieved (abscess drained, catheter removed)
• Patient is clinically stable without septic shock or high APACHE scores

Critical Limitations of Ertapenem vs. Meropenem:

Ertapenem has a narrower spectrum and lacks activity against Pseudomonas aeruginosa and Enterococcus species 3. While P. stuartii is naturally sensitive to carbapenems 4, ertapenem demonstrates stronger porin-mediated translocation through P. stuartii outer membrane proteins (OmpPst1) compared to other beta-lactams 5, which supports its use when susceptible.

However, meropenem remains superior for severe P. stuartii infections, as demonstrated in a periprosthetic joint infection case requiring prolonged meropenem infusion 6. The 4-hour half-life of ertapenem versus 1-hour for meropenem means less frequent dosing but potentially suboptimal time above MIC in critically ill patients 3.

Clinical Algorithm

Step 1: Assess Infection Severity

• Severe infection (bacteremia, VAP, severe sepsis): Ertapenem is suboptimal; consider combination therapy with available agents
• Non-severe infection (cUTI, mild SSI): Ertapenem monotherapy acceptable if susceptible

Step 2: Verify Susceptibility

• Must have documented ertapenem susceptibility—P. stuartii can develop carbapenem resistance through porin loss 5, 7
• If only meropenem susceptibility available without ertapenem testing, do not assume cross-susceptibility

Step 3: Consider Patient Factors

• Hypoalbuminemia: Ertapenem is highly protein-bound (95%); critically ill patients with albumin <2.5 g/dL may have unpredictable clearance 8
• Renal function: Dose adjust to 500 mg daily if CrCl ≤30 mL/min 1
• Prior antibiotic exposure: P. stuartii HAIs often follow colistin therapy and prolonged hospitalization 7

Step 4: Dosing Strategy

• Standard dose: 1 gram IV daily for adults 1
• Duration: 10-14 days for complicated UTI/pyelonephritis; 5-14 days for intra-abdominal infections 1
• Consider therapeutic drug monitoring in critically ill or hypoalbuminemic patients, though data are limited 8

Important Caveats

Antibiotic Stewardship Considerations:

The 2022 ESCMID guidelines emphasize that for non-severe infections with resistant Enterobacterales, using "old antibiotics" based on individual susceptibility is good clinical practice rather than reflexively using carbapenems 2. If the isolate shows susceptibility to fluoroquinolones or aminoglycosides despite initial resistance reporting, de-escalation after 2-3 days should be strongly considered 9.

Risk of Treatment Failure:

In a comparative study of ESBL-producing Enterobacterales bacteremia in critically ill patients, ertapenem had significantly higher rates of antibiotic escalation (33.3% vs 2.8%) compared to meropenem, though overall clinical failure rates were similar 8. This suggests ertapenem may be adequate for stable patients but has a higher risk of requiring treatment modification.

Resistance Mechanisms:

P. stuartii can develop carbapenem resistance through loss of OmpPst1 porin expression when exposed to carbapenems in growth media 5. Additionally, carbapenem-resistant P. stuartii carrying blaNDM or blaIMP genes has been documented in healthcare-associated outbreaks 7. If the patient fails ertapenem therapy, repeat cultures and consider metallo-beta-lactamase production.

Alternative Strategies When Ertapenem is Inadequate:

• Combination therapy: If severe infection and only older agents available, consider aminoglycoside + another active agent based on susceptibilities 2
• Ceftazidime-avibactam or cefiderocol: Reserve for extensively resistant isolates if available 2
• Source control: Absolutely critical—remove infected hardware, drain abscesses, remove catheters 6

Bottom line: Ertapenem is a reasonable alternative to meropenem for susceptible P. stuartii in non-severe infections with adequate source control, but maintain a low threshold for escalation if clinical response is inadequate within 48-72 hours 9, 8.